临床试验中人工智慧市场规模、份额和成长分析：按交付方式、人工智慧技术类型、临床试验阶段、治疗领域、应用、最终用户和地区划分——2026-2033年产业预测

2024年全球临床试验人工智慧市场价值为18.7亿美元，预计将从2025年的21.8亿美元成长到2033年的75.7亿美元。预测期（2026-2033年）的复合年增长率预计为16.8%。

全球临床试验人工智慧市场的发展动力源于缩短研发週期和控制不断攀升的研发成本的迫切需求，促使申办方在整个试验流程中实施自动化。该领域涵盖了先进的演算法和平台，能够增强患者识别、预测保留率、标准化终点评估和提供自适应设计支持，从而加快核准并最大限度地降低成本。从传统生物统计学到先进机器学习的演进反映了电子健康记录和基因组资料库等资料来源的成熟。整合多样化的资料流提高了模型的通用性，能够更准确地识别伫列和预测安全性讯号，从而减少筛检失败并缩短入组时间。此外，人工智慧透过自动化合格评估和患者招募提高了患者招募效率，最终促进了分散式试验的发展并刺激了投资。

全球人工智慧市场在临床试验中的驱动因素

人工智慧在临床试验领域的全球市场正受到人工智慧技术快速普及的显着推动。人工智慧能够优化受试者配对、改进试验通讯协定、优化研究中心选择并简化招募流程。这种整合最大限度地减少了延误，提高了研究的可行性。人工智慧能够从电子健康记录和真实世界数据中准确识别合格的患者，从而提高入组效率并确保通讯协定的依从性。此外，先进的预测模型有助于优化资源分配和风险管理，促使申办方采用人工智慧解决方案。这种营运效率的提升，加上人们对试验品质改善的预期，正在推动人工智慧被更广泛地接受并无缝整合到临床开发工作流程中。

全球人工智慧市场在临床试验中面临的限制因素

由于严格的患者隐私法规和日益增长的资料安全担忧，全球临床试验领域的人工智慧市场面临严峻挑战。这些问题限制了对关键临床数据集的访问，而这些数据集对于开发有效的人工智慧模型至关重要。匿名化复杂临床数据和确保区域合规性方面的挑战，使得集中式资料存取变得困难，并阻碍了机构间的合作。这进一步增加了供应商的难度，并可能透过限制可用于演算法训练的资料多样性，影响人工智慧模型的可靠性和适用性。因此，在建立适当的隐私保护措施和管治策略之前，各机构可能会选择推迟或限制在临床试验中采用人工智慧。

全球人工智慧市场在临床试验中的趋势

在全球临床试验人工智慧市场，一个重要趋势正在兴起：将真实世界数据（RWE）整合到其框架中。人工智慧平台能够熟练地处理各种临床和真实世界资料来源，从而提高试验设计、患者选择和结果评估中使用的证据品质。这项进步使人工智慧能够识别各种医疗保健环境和非结构化资料中的模式，从而使试验结果与常规临床实践更加紧密地结合。随着申办者和研究人员越来越重视互通模型和可解释的输出，将观察性研究结果转化为可操作的试验假设的趋势日益明显。这打破了证据孤岛，提高了试验结果在常规医疗保健中的相关性和效用。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球人工智慧临床试验市场规模：依产品/服务及复合年增长率划分（2026-2033 年）

• 软体
• 服务
• 硬体

全球人工智慧临床试验市场规模：按人工智慧技术类型和复合年增长率划分（2026-2033 年）

• 机器学习
  • 监督式学习
  • 无监督学习
• 深度学习
• 自然语言处理（NLP）
• 电脑视觉

全球人工智慧临床试验市场规模：依临床试验阶段及复合年增长率划分（2026-2033 年）

• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

全球人工智慧临床试验市场规模：按治疗领域和复合年增长率划分（2026-2033 年）

• 肿瘤学
• 感染疾病
• 神经病学
• 循环系统
• 代谢性疾病
• 免疫学
• 其他的

全球人工智慧临床试验市场规模：按应用及复合年增长率划分（2026-2033 年）

• 病人招募/留存
• 测试设计和通讯协定优化
• 数据管理与分析
• 监测和安全监视
• 药物发现支持

全球人工智慧临床试验市场规模：按最终用户和复合年增长率划分（2026-2033 年）

• 製药公司
• 生技公司
• 合约研究组织（CRO）
• 学术和研究机构
• 医院和临床中心

全球人工智慧市场规模及临床试验复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Medidata（Dassault Systmes）
• IQVIA
• Unlearn.ai
• Owkin
• Saama Technologies
• AiCure
• Deep6.ai
• Exscientia
• Antidote Technologies
• BioSymetrics
• Euretos
• Ardigen
• Mendel AI
• Phesi
• ICON plc
• Parexel
• Syneos Health
• nference
• ConcertAI
• SAS Institute

结论与建议

Global Ai In Clinical Trials Market size was valued at USD 1.87 Billion in 2024 and is poised to grow from USD 2.18 Billion in 2025 to USD 7.57 Billion by 2033, growing at a CAGR of 16.8% during the forecast period (2026-2033).

The global AI in clinical trials market is driven by the imperative to reduce development timelines and manage escalating R&D costs, leading sponsors to implement automation throughout trial processes. This sector encompasses advanced algorithms and platforms that enhance patient identification, retention predictions, endpoint assessment standardization, and adaptive design support, subsequently expediting approvals and minimizing expenditures. The evolution from traditional biostatistics to sophisticated machine learning reflects the maturation of data sources, such as electronic health records and genomic databases. The integration of diverse data streams enhances model generalizability, enabling more precise cohort identification and safety signal predictions, which decreases screening failures and enrollment periods. Additionally, AI facilitates patient recruitment efficiency by automating eligibility assessments and outreach, ultimately fostering opportunities for decentralized trials and stimulating investments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ai In Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ai In Clinical Trials Market Segments Analysis

Global ai in clinical trials market is segmented by offering, ai technology type, clinical trial phase, therapeutic area, application, end user and region. Based on offering, the market is segmented into Software, Services and Hardware. Based on ai technology type, the market is segmented into Machine Learning, Deep Learning, Natural Language Processing (NLP) and Computer Vision. Based on clinical trial phase, the market is segmented into Phase I, Phase II, Phase III and Phase IV. Based on therapeutic area, the market is segmented into Oncology, Infectious Diseases, Neurology, Cardiovascular, Metabolic Disorders, Immunology and Others. Based on application, the market is segmented into Patient Recruitment & Retention, Trial Design & Protocol Optimization, Data Management & Analytics, Monitoring & Safety Surveillance and Drug Discovery Support. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes and Hospitals & Clinical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ai In Clinical Trials Market

The global market for AI in clinical trials is significantly driven by the swift adoption of AI technologies, which optimize participant matching and enhance trial protocols, site selection, and recruitment processes. This integration minimizes delays and boosts the feasibility of studies. AI's capability to accurately identify eligible patients from electronic health records and real-world data enhances enrollment efficiency and ensures adherence to protocols. Moreover, advanced predictive modeling fosters improved resource allocation and risk management, motivating sponsors to embrace AI solutions. These operational efficiencies, along with perceived enhancements in trial quality, promote wider acceptance and seamless incorporation of AI into clinical development workflows.

Restraints in the Global Ai In Clinical Trials Market

The Global AI in Clinical Trials market faces significant challenges due to stringent regulations surrounding patient privacy and escalating concerns over data security. These issues restrict access to essential clinical datasets needed for developing effective AI models. The complexities associated with de-identifying nuanced clinical data and ensuring compliance across different regions complicate centralized data access and inhibit collaboration between institutions. This creates additional hurdles for vendors, ultimately limiting the diversity of data available for algorithm training, which can affect the reliability and applicability of AI models. Consequently, organizations may opt to postpone or limit the implementation of AI in clinical trials until adequate privacy protections and governance strategies are put in place.

Market Trends of the Global Ai In Clinical Trials Market

The Global AI in Clinical Trials market is witnessing a significant trend towards the integration of Real World Evidence (RWE) within its frameworks. AI platforms are adeptly processing diverse clinical and real-world data sources, enhancing the richness of evidence utilized for trial design, patient selection, and outcome assessment. This advancement fosters a closer alignment between trial results and routine clinical practices, as AI enables pattern recognition across varying care settings and unstructured data. As sponsors and investigators increasingly emphasize the need for interoperable models and explainable outputs, the translation of observational insights into actionable trial hypotheses is becoming more prevalent, effectively bridging evidence silos and boosting the relevance and utility of trial findings in everyday healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global AI in Clinical Trials Market Size by Offering & CAGR (2026-2033)

• Market Overview
• Software
• Services
• Hardware

Global AI in Clinical Trials Market Size by AI Technology Type & CAGR (2026-2033)

• Market Overview
• Machine Learning
  • Supervised Learning
  • Unsupervised Learning
• Deep Learning
• Natural Language Processing (NLP)
• Computer Vision

Global AI in Clinical Trials Market Size by Clinical Trial Phase & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III
• Phase IV

Global AI in Clinical Trials Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Infectious Diseases
• Neurology
• Cardiovascular
• Metabolic Disorders
• Immunology
• Others

Global AI in Clinical Trials Market Size by Application & CAGR (2026-2033)

• Market Overview
• Patient Recruitment & Retention
• Trial Design & Protocol Optimization
• Data Management & Analytics
• Monitoring & Safety Surveillance
• Drug Discovery Support

Global AI in Clinical Trials Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Hospitals & Clinical Centers

Global AI in Clinical Trials Market Size & CAGR (2026-2033)

• North America (Offering, AI Technology Type, Clinical Trial Phase, Therapeutic Area, Application, End User)
  • US
  • Canada
• Europe (Offering, AI Technology Type, Clinical Trial Phase, Therapeutic Area, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Offering, AI Technology Type, Clinical Trial Phase, Therapeutic Area, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Offering, AI Technology Type, Clinical Trial Phase, Therapeutic Area, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Offering, AI Technology Type, Clinical Trial Phase, Therapeutic Area, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Medidata (Dassault Systmes)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Unlearn.ai
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Owkin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Saama Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AiCure
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deep6.ai
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exscientia
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Antidote Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSymetrics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euretos
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ardigen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mendel AI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phesi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• nference
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ConcertAI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SAS Institute
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations